Head-To-Head Analysis: XOMA Corporation (XOMA) and Trillium Therapeutics (TRIL)

XOMA Corporation (NASDAQ: XOMA) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Risk and Volatility

XOMA Corporation has a beta of 3.05, indicating that its share price is 205% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Earnings & Valuation

This table compares XOMA Corporation and Trillium Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
XOMA Corporation $12.31 million 11.29 -$30.55 million ($7.32) -2.50
Trillium Therapeutics N/A N/A -$27.43 million ($3.73) -1.27

Trillium Therapeutics has higher revenue, but lower earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

32.9% of XOMA Corporation shares are held by institutional investors. Comparatively, 48.0% of Trillium Therapeutics shares are held by institutional investors. 3.0% of XOMA Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares XOMA Corporation and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XOMA Corporation -329.42% N/A -155.46%
Trillium Therapeutics N/A -178.08% -61.40%

Analyst Recommendations

This is a summary of current recommendations for XOMA Corporation and Trillium Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Corporation 0 2 2 0 2.50
Trillium Therapeutics 0 0 6 0 3.00

XOMA Corporation presently has a consensus price target of $17.00, indicating a potential downside of 7.05%. Trillium Therapeutics has a consensus price target of $16.50, indicating a potential upside of 247.37%. Given Trillium Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than XOMA Corporation.


Trillium Therapeutics beats XOMA Corporation on 8 of the 12 factors compared between the two stocks.

About XOMA Corporation

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply